Table 1.
Clinical characteristics of study participants.
| HC (n=34) | aCD20-MS (n=43) | P value a | |
|---|---|---|---|
| Age, mean years [range] | 34.7 [23-59] | 53.9 [28-82] | |
| Relapsing Remitting (RRMS) | 48.4 [28-74] | <0.001 | |
| Progressive (PMS) | 63.2 [35-82] | <0.001 | |
| Gender, n (%) | |||
| Male | 8 (23.5) | 16 (37.2) | 0.198 |
| Female | 26 (76.5) | 27 (62.8) | |
| MS type, n (%) | |||
| RRMS | 27 (62.8) | ||
| PMS | 16 (37.2) | ||
| anti-CD20 therapy, n (%) | |||
| Ocrelizumab | 27 (62.8) | ||
| Rituximab | 16 (37.2) | ||
| Vaccine type, n (%) | |||
| BNT162b2 (Pfizer-BioNTech) | 33 (97.1) | 22 (51.2) | |
| mRNA-1273 (Moderna) | 1 (2.9) | 18 (41.8) | |
| Ad26.COV2.S (J&J-Janssen) | 3 (7) | ||
| Last infusion to 1st dose vaccination interval, median days [IQR] | 114.5 [81-138.5] | ||
| RRMS | 117.5 [89-139.2] | ||
| PMS | 114.5 [71.2-139.2] | ||
| Full vaccination to collection interval, median days [IQR] | 63 [59.7-90] | 64 [42-93] | 0.406 |
| CD3+/4+/8+ absolute count, mean cell/μL [reference range] | |||
| CD3+ | 1250 [721-2704] | ||
| CD4+ | 922 [423-1614] | ||
| CD8+ | 325 [143-1039] | ||
| CD4+/CD8+ ratio [reference range] | 3.9 [0.9-4.3] | ||
| CD19+ absolute count > 20 cell/μL, n (%) | 3 (7) | ||
Clinical characteristics of vaccinated multiple sclerosis patients treated with anti-CD20 (aCD20-MS) and healthy control (HC) cohorts. IQR, interquartile range.
a
Statistical significance of differences in the age and full vaccination to collection interval of the groups was assayed by Mann-Whitney U tests; statistical significance of differences in the distribution of female/male was assayed with Chi-square test.